Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Submission seeks approval for treatment of an abnormal heart rhythm, Paroxysmal Supraventricular Tachycardia or PSVT Comprehensive data package includes positive results from pivotal Phase 3 RAPID trial which Company believes demonstrates...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news